The Lancet Oncology · 2012 · 452 citations · 68 references
MedicineGeneticsOncologyCancer GeneticsMolecular OncologyTumor HeterogeneityCancer PharmacogenomicsChemotherapy ResistanceDrug ResistanceGenetic HeterogeneityResistance GenesTherapeutic ResistanceAnticancer Drug ResistanceIntertumor Genetic HeterogeneityIntratumor Genetic HeterogeneityMolecular Drug ResistanceTherapeutic Resistance Mechanisms
68
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations
Medicine, Oncology, Pharmacology +13
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, Edith A. Perez, John Bryant et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text
Medicine, Oncology, Pharmacology +16
MUTATIONS OF BACTERIA FROM VIRUS SENSITIVITY TO VIRUS RESISTANCE
S. E. Luria, M. Delbrück · Genetics · 1943 · 3.9K citations